ZZ Biotech announces Phase 2 Trial

April 22, 2014: ZZ Biotech announces Phase 2 Trial with 3K3A-APC in Stroke; Funds will be provided by NIH and Broadview Ventures
ZZ Biotech today announced that the National Institutes of Health will support a multicenter Phase 2 clinical trial of its experimental drug, 3K3A-APC, in patients suffering from acute ischemic stroke.

 

Press Release